Procedure | 6 cycles arm (n = 29) | >6 cycles arm (n = 30) | |
Surgery | |||
Biopsy | 6 (20.7%) | 5 (16.7%) | |
Partial resection | 9 (31.0%) | 12 (40.0%) | |
Total gross resection | 14 (48.3%) | (43.3%) | |
Treatment events |
|
| |
-Surgery only | 3 (10.3%) | 3 (10%) | |
-Surgery CCRT | 26 (89.6%) | 27 (90%) | |
-Radiotherapy to PTV (mean) | 59.0 Gy ± (SD 2.58) | 58.97 Gy ± (SD 2.23) | |
-Completed CCRT | 21 (72.4%) | 22 (73.3%) | |
(Cause of un completion) | -Toxicity | 1 (3.8%) | 2 (7.4%) |
-Clinical deterioration | 4 (15.3%) | 3 (11.1%) | |
-Adjuvant TMZ |
|
| |
<6 cycles adjuvant TMZ | 5 (17.2%) | 3 (13.6%) | |
6 cycles adjuvant TMZ | 16 (76.1%) |
| |
>6 cycles adjuvant TMZ |
| 19 (86.3%) | |
Median No. of cycles |
| 11 | |
(Range) |
| (8 - 23 cycle) | |
Completed CCRT & adjuvant | N = 16 (55.1%) | N = 19 (63.3%) | |
Median PFS (month) | 12.1 | 18.8 (P 0.01) | |
Median OS (month) | 18.1 | 24.1 (P 0.04) | |
Median time to progression from last TMZ dose (month) | 4.1 (1.3 - 16.5) | 6.8 (1.8 - 20) | |
Treatment post progression |
|
| |
Surgery | 4 (25.0%) | 5 (26.3%) | |
TMZ 4 weekly | 5 (31.3%) | 3 (31.6%) | |
TMZ alternative schedule | 3 (18.8%) | 2 (10.5%) | |
Bevacizumab | 3 (18.8%) | 4 (21.0%) | |
All patients | N = 29 | N = 30 | |
Median PFS (month) | 10.4 | 13.2 (P 0.038) | |
Median OS (month) | 14.1 | 18.8 (P 0.07) | |
Treatment post progression |
|
| |
Surgery | 4 (13.7%) | 5 (16.6%) | |
TMZ 4 weekly | 6 (20.7%) | 8 (26.7%) | |
TMZ alternative schedule | 3 (10.3%) | 3 (10.0%) | |
Bevacizumab | 4 (13.7 %) | 4 (13.3%) | |
G3/4 toxicity |
|
| |
On CCRT | N = 26 | N = 27 | |
Thrombocytopenia | 1 (3.8%) | 2 (7.4%) | |
Neutropenia | 1 (3.8%) | 0 | |
On adjuvant TMZ | N = 21 | N = 22 | |
Thrombocytopenia | 1 (4.7%) | 2 (9.0%) | |
Neutropenia | 2 (7.6%) | 4 (18%) | |
Anemia | 0 | 1 (4.5%) |